Among others, inhibition of signaling pathways (JAK2, PI3K/Akt/mTOR, Wnt/βcatenin, etc.), immunological approaches (Interferon-α (IFNα), vaccination, etc.)or niche targeting (stromal cytokines, stroma adhesion, etc.)are proposed in CML to reach stem cells [80–83]. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.